RxDoctor Payments Data

Rachel Hoins, PA

Physician Assistant · Kansas City, MONPI 1154891299

Payments from drug & device makers

$1,653in general payments, 2019–2025

Across 56 payments — averaging $29.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$345
  • Baudax Bio Inc.$185
  • Amgen$169
  • Neurocrine Biosciences, Inc.$148
  • Lilly USA, LLC$139
  • Axsome Therapeutics, Inc.$119
  • plus $548 from 9 others

What the payments were for

  • Food & beverage$1,653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,653 in reported general payments places this provider in the 80th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$2,999
Medicare patients
24
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate156$156,099
Kesimpta PenOfatumumab12$95,381
Emgality PenGalcanezumab-Gnlm78$65,625
Aimovig AutoinjectorErenumab-Aooe74$53,093
Ajovy AutoinjectorFremanezumab-Vfrm32$25,342
UbrelvyUbrogepant16$22,497
Dalfampridine ErDalfampridine17$8,341
Eletriptan HbrEletriptan Hydrobromide13$3,428
Divalproex Sodium37$1,155
Tetrabenazine11$838
Baclofen22$795
RizatriptanRizatriptan Benzoate16$642
Topiramate62$628
Amitriptyline Hcl49$409
Gabapentin37$350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$345$22,49716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →